Geoffrey is Co-Founder, Chief Innovation Officer, and Board Director for Indigo, as well as General Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in nutrition, environmental sustainability, and medicine. Geoffrey has created companies that include Tessera Therapeutics, Generate Biomedicines, Sana Biotechnology, Kaleido Biosciences (NASDAQ:KLDO), Seres Therapeutics (NASDAQ:MCRB), and Axcella Health (NASDAQ:AXLA).

    Geoffrey previously served as Chief Executive Officer of Kaleido Biosciences and Chief Technology Officer at Seres Therapeutics, where he led the build-out of their human microbiome R&D platforms and the discovery of the first clinically-validated microbiome therapeutics. He was also Chief Executive Officer of Cobalt Biomedicine, which merged with Sana Biotechnology.

    Geoffrey has been recognized with numerous patent grants, awards, and publications. He is listed as an inventor on over 200 patent applications and patents, was cited by Frontiers in Bioengineering and Biotechnology as the most prolific inventor in the microbiome field, and has co-authored more than 20 peer-reviewed publications. Geoffrey has received a number of awards and honors, including Bloomberg 50's Ones to Watch; Business Insider’s 30 Biotech Leaders Under 40; Endpoints 20 Biopharma Leaders Under 40; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative students at MIT; and the National Inventors Hall of Fame Graduate Student Prize. Geoffrey and his inventions have been profiled by Forbes, The Economist, CNN, Bloomberg Businessweek, Scientific American, Popular Science, MIT Technology Review, and other media.

    Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.